Publications by authors named "M W Taal"
Objective: To develop and validate a prognostic model for risk-stratified monitoring of 5-aminosalicylate nephrotoxicity.
Methods: This UK retrospective cohort study used data from the Clinical Practice Research Datalink Aurum and Gold for model development and validation respectively. It included adults newly diagnosed with inflammatory bowel disease and established on 5-aminosalicylic acid (5-ASA) treatment between 1 January 2007 and 31 December 2019.
The ultimate goal of precision medicine is to tailor treatment to specific disease processes, thereby optimising patient outcomes. This approach moves beyond the one-size-fits-all model, recognising at an individual level the unique combinations of molecular, genetic, and environmental factors determining disease progression and treatment response. Chronic kidney disease (CKD) exemplifies the need for precision medicine, given its complex and heterogeneous nature.
View Article and Find Full Text PDFIntroduction: The Kidney BEAM randomized controlled trial reported clinically meaningful and statistically significant improvements in mental health-related quality of life (HRQoL), physical function (sit-to-stand-60, but not the physical component of HRQoL) and patient activation after a 12-week physical activity digital health intervention (DHI). This study explores factors that contributed to the effectiveness of Kidney BEAM through mixed methods analyses.
Methods: Quantitative data analysis was obtained from the recently published primary manuscript.
Introduction: There is inequity in the provision of physical rehabilitation services for people living with chronic kidney disease (CKD). The Kidney BEAM trial evaluated the clinical value and cost effectiveness of a physical activity digital health intervention (DHI) in CKD.
Methods: In a single-blind, 11 center, randomized controlled trial, 340 adult participants with CKD were randomly assigned to either the Kidney BEAM physical activity DHI or a waitlist control.
Article Synopsis
- The study evaluates risks associated with Chronic Kidney Disease (CKD) across different primary renal diseases using data from a UK cohort of nearly 3,000 adults.
- It found that over a median follow-up of about 49 months, many participants experienced kidney failure or death, with significant differences in risk based on the primary renal diagnosis (PRD), even after adjusting for factors like age and blood pressure.
- The research highlights that while eGFR is a reliable predictor of kidney outcomes, the effectiveness of albuminuria (uACR) as a predictive marker varies greatly depending on the type of kidney disease, suggesting that personalized treatment strategies are essential in CKD management.